NLNK - NewLink Genetics Corporation
| Previous Close | 5.40 |
| Open | 5.42 |
| Bid | 5.19 x 2900 |
| Ask | 5.55 x 1000 |
| Day's Range | 5.36 - 5.50 |
| 52 Week Range | 3.75 - 19.30 |
| Volume | 365,924 |
| Avg. Volume | 1,137,290 |
| Market Cap | 200.692M |
| Beta | 1.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Thomson Reuters StreetEvents•19 days ago
Edited Transcript of NLNK earnings conference call or presentation 3-May-18 8:30pm GMT
Q1 2018 NewLink Genetics Corp Earnings Call
- Associated Press•24 days ago
NewLink: 1Q Earnings Snapshot
The Ames, Iowa-based company said it had a loss of 49 cents per share. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for ...
- Investor's Business Daily•last month
NewLink Shares Bite The Dust After Merck-Incyte Melanoma Failure
NewLink toppled Monday after it scrapped a late-stage study of its immuno-oncology drug in combination with drugs from Merck and Bristol.
- MarketWatch•last month
NewLink shares fall on late-stage trial changes
NewLink Genetics Corp. shares fell as much as 15% in premarket trade Monday after the company said it won't proceed as planned with a late-stage trial of its indoximod for advanced melanoma. The company ...
- Zacks•2 months ago
NewLink Shares Plunge After Incyte & Merck's Study Fails
Shares of NewLink Genetics Corp. (NLNT) plunged about 42.6% following the news of the failure of Incyte and Merck's phase III combination study for metastatic melanoma.
- Benzinga•2 months ago
Benzinga's Top Analyst Calls From April 9, 2018
Argus raises IQVIA Holdings Inc. (NYSE: IQV ) price target from $110 to $112, says contract research organizations will benefit from “steady biopharmaceutical funding and a healthy backlog”; Firm raises ...
- Benzinga•2 months ago
NewLink Genetics' Potential Catalysts Not Enough To Justify A Bullish Stance, Baird Says In Downgrade
NewLink Genetics Corp (NASDAQ: NLNK ) said Friday it will review the clinical programs for its indoximod therapy after rival Incyte Corporation (NASDAQ: INCY ) announced disappointing results from a study ...
- Benzinga•2 months ago
Cantor Fitzgerald Double Downgrades NewLink Genetics After Incyte's Disappointing Trial
NewLink Genetics Corp (NASDAQ: NLNK ), a late-stage biopharmaceutical company that focuses on cancer treatments, said on Friday it will review its clinical program after Merck & Co., Inc. (NYSE: MRK ) ...
- Zacks•2 months ago
Incyte's Epacadostat Fails in Melanoma Study, Shares Plunge
Incyte's (INCY) epacadostat in combination with Merck's Keytruda fails to meet primary endpoint of PFS in a phase III melanoma study.
- MarketWatch•2 months ago
NewLink will review clinical programs after Merck, Incyte trial failure
NewLink Genetics Corp. plans to review its clinical programs after the failure of a similar drug in a Merck and Incyte clinical trial. NewLink noted that the mechanism of its drug, an IDO pathway inhibitor ...
- Benzinga•2 months ago
Benzinga's Top Analyst Calls From April 6, 2018
These headlines first appeared on Benzinga Pro . Cantor out defending NewLink Genetics Corp (NASDAQ: NLNK ), says indoximod is differentiated vs epacadostat in response rates in more heavily pretreated ...
- Motley Fool•2 months ago
Why Incyte and NewLink Genetics Crashed Today
There's bad news on the clinical trial front.
- MarketWatch•2 months ago
NewLink Genetics shares plummet 39% after Merck, Incyte trial failure
NewLink Genetics Corp. shares plummeted 39.2% in premarket trade Friday after Merck and Incyte Corp. said their trial testing a combination including a type of cancer drug called an IDO inhibitor had failed. ...
- Zacks•2 months ago
Options Traders Expect Huge Moves in NewLink Genetics (NLNK) Stock
Surging implied volatility makes NewLink Genetics (NLNK) stock lucrative to the option traders.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of NLNK earnings conference call or presentation 1-Mar-18 9:30pm GMT
Q4 2017 NewLink Genetics Corp Earnings Call
- Associated Press•3 months ago
NewLink reports 4Q loss
The Ames, Iowa-based company said it had a loss of 37 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss ...
- Insider Monkey•3 months ago
Zogenix Inc. (ZGNX) and Arena Pharmaceuticals, Inc. (ARNA) Helped This Healthcare-Focused Fund Earn Double-Digit Returns
It’s no secret that hedge funds have been underperforming the market by quite a wide margin in the last couple of years. However, in the industry that encompasses hundred of hedge funds and has gathered over $3.0 trillion in assets under management, there still are many players that posted great returns. This is particularly the […]
- Simply Wall St.•4 months ago
What Do Analysts Think About NewLink Genetics Corporation’s (NASDAQ:NLNK) Earnings Trend?
The latest earnings announcement NewLink Genetics Corporation’s (NASDAQ:NLNK) released in September 2017 suggested that losses became smaller relative to the prrior year’s level as a result of recent tailwinds TodayRead More...
- Thomson Reuters StreetEvents•7 months ago
Edited Transcript of NLNK earnings conference call or presentation 2-Nov-17 12:30pm GMT
Q3 2017 NewLink Genetics Corp Earnings Call
- Associated Press•7 months ago
NewLink reports 3Q loss
The Ames, Iowa-based company said it had a loss of 69 cents per share. The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for ...
- TheStreet.com•7 months ago
NewLink Jumps on Orphan Drug Status for Melanoma Treatment -- Biotech Movers
The U.S. Food and Drug Administration has granted orphan drug designation to NewLink's indoximod, a potential treatment for patients with Stage IIb-IV melanoma.
- Capital Cube•7 months ago
ETFs with exposure to NewLink Genetics Corp. : October 16, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to NewLink Genetics Corp. Here are 5 ETFs with the largest exposure to NLNK-US. Comparing the performance and risk of NewLink Genetics Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- Benzinga•7 months ago
Bank Of America Sees NewLink Genetics As 'Undervalued'
Reasoning that NewLink Genetics Corp (NASDAQ: NLNK ) shares are undervalued, Bank of America Merrill Lynch initiated coverage at Buy with a $22 price target. At time of writing, shares were rallying 8.45 ...
- Motley Fool•8 months ago
The 1 Event That Sent NewLink Genetics Corporation Soaring 25% in September
New data on NewLink's lead drug puts some pep in this clinical-stage drug developers' step.
- Motley Fool•8 months ago
Here's Why NewLink Genetics Corp. Stock Is Surging Again Today
An anticipated secondary offering appears to be priced better than expected.
